drugset / Trial / NCT03540953

Endoscopic Injection of Mitomycin C for the Treatment of Pharyngoesophageal Stenosis

NCT03540953

Terminated 12 enrolled Fauze Maluf Filho
NaSingle-groupOpen-labelTreatment

Summary

Management of pharyngoesophageal stenosis (PES) in patients after head and neck cancer (HNC) treatment remains a challenge. There are some cases of strictures refractory to dilation sessions. This study aimed to evaluate the efficacy of Mitomycin C (MMC) endoscopic injection for the treatment of refractory pharyngoesophageal stenosis. Patients and methods: This is a prospective study in patients with dysphagia following head and neck cancer treatment, without evidence suggestive of tumor recurrence, and refractory to endoscopic treatment. Theses undergo endoscopic dilation of the stenotic segment with thermoplastic bougies, followed by the injection of MMC.

Timeline

Start
2015-01-05
Primary completion
2015-05-05
Completion
2018-01-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Mitomycin C Other / unclassified 3 mg Other